Door to needle time in administering thrombolytic therapy for acute myocardial infarction

Saudi Medical Journal

Volumn 24, Issue 4, 2003, Pages 361-364

  Abba, Abdullah A ^a   Wani A , Bashir ^b   Rahmatullah, Rehan A ^a   Khalil, Mohamed Z ^a   Kumo, Abubakar M ^a   Ghonaim, Mohammed A ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; NITRATE;

ACUTE HEART INFARCTION; ARTICLE; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; FIBRINOLYTIC THERAPY; HOSPITAL ADMISSION; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; SAUDI ARABIA; THORAX PAIN; TIME;

EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; MEDICAL AUDIT; MYOCARDIAL INFARCTION; SAUDI ARABIA; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 0038531134     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 8610: 525-530.
2. Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988 8607: 349-360.
3. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 8585: 545-549.
4. Linderer T, Schroder R, Arntz R, Heineking ML, Wunderlich W, Kohl K et al. Prehospital thrombolysis: beneficial effects of very early treatment on infarct size and left ventricular function. J Am Coll Cardiol 1993; 22: 1304-1310.
5. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311.
6. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996; 9030: 771-775.
7. Timm TC, Ross R, Braunwald E. Left ventricular function and early cardiac events as a function of time to treatment with t-PA: A report from TIMI II. Circulation 1991; 84: II.
8. Gurwitz JH, McLaughlin TJ, Willison DJ, Guadadnoli E, Hauptman PT, Gao X et al. Delayed hospital presentation in patients who have had acute myocardial infarction. Ann Intern Med 1997; 126: 593-599.
9. Hirvonen TP, Halinen MO, Kala RA, Olkinuora JT. Delays in thrombolytic therapy for acute myocardial infarction in Finland. Results of a national thrombolytic therapy delay study. Finnish Hospitals Thrombolysis Survey Group. Eur Heart J 1998; 19: 885-892.
10. Goff DC Jr, Sellers DE, McGovern PG, Meischke H, Goldberg RJ, Bittner V et al for the REACT Study Group. Knowledge of heart attack symptoms in a population survey in the United States: The REACT trial (Rapid Early Action for Coronary Treatment). Arch Intern Med 1998; 158: 2329-2338.
11. Sharkey SW, Bruneete DD, Ruiz E, Hession WT, Wysham DG, Goldenberg IF et al. An analysis of time delays preceding thrombolysis for acute myocardial infarction. JAMA 1989; 262: 3171-3174.
12. Chan WK, Lam KN, Lau FL, Tang FM. Starting thrombolytic therapy for patients with acute myocardial infarction in Accident and Emergency Department: from implementation to evaluation. Chin Med J (Engl) 1998; 111: 291-294.
13. Kelion AD, Banning AP, Shahi M, Bell JA. The effect of reduction of door to needle times on the administration of thrombolytic therapy for acute myocardial infarction. Postgrad Med J 1998; 875: 533-536.
14. Lamfers EJ, Hooghoudt TE, Uppelschoten A, Stolwijk PW, Verheugt FW. Effect of prehospital thrombolysis on aborting acute myocardial infarction. Am J Cardiol 1999; 84: 928-930, A6-A7.
15. Rawles J, on behalf of the GREAT Group. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994; 23: 1-5.
16. Rawles JM. Quantification of the benefit of earlier thrombolytic therapy: Five-year results of the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1997; 30: 1181-1186.
17. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ et al. Pre-hospital initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA 1993; 270: 1211-1216.
18. Morrison LJ, Verbeek PR, McDonald AC, Saedsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA 2000; 283: 2686-2692.
19. Somauroo JD, McCarten P, Appleton B, Amadi A, Rodrigues E. Effectivness of a thrombolysis nurse in shortening delay to thrombolysis in acute myocardial infarction. J R Coll Physicians Lond 1999; 33: 46-50.